Brian Rini, MD

Brian Rini is an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development. In January 2020, he joined Vanderbilt-Ingram Cancer Center (VICC) as the inaugural chief of Clinical Trials. He is an Ingram Professor of Medicine and leads kidney cancer clinical research efforts, in addition to the new role, which focuses on expanding oncology clinical research operations and training opportunities in clinical cancer research. Dr. Rini was chair of the Oncologic Drugs Advisory Committee for the U.S. Food and Drug Administration (FDA) in 2018-2019 and completed a four-year term on that committee. He was a founding member of the Kidney Cancer Programmatic Panel for the Department of Defense Congressionally Directed Medical Research Programs, spearheading the launch of what is now the largest source of kidney cancer research support in the nation, directing more than $20 million in grant funding to kidney cancer basic, translational and clinical investigations. Dr. Rini was previously at the Cleveland Clinic, where he served as director of the Genitourinary Cancer Program and professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.